Royalty Pharma plc Increase (Decrease) in Accounts Payable and Accrued Liabilities
Royalty Pharma plc (RPRX) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $3.06 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-05
- Royalty Pharma plc increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $8.13M.
- Royalty Pharma plc increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$5.08M, a 150.36% decline year-over-year.
- Royalty Pharma plc increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$28.53M.
- Royalty Pharma plc increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $10.91M, a 51.44% increase year-over-year.
- Royalty Pharma plc increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$13.93M.
- Royalty Pharma plc increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$2.29M, a 136.72% decline from fiscal 2023.
- Royalty Pharma plc increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $6.24M, a 172.79% increase from fiscal 2022.
- Royalty Pharma plc increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $2.29M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $3.06M 10-Q · filed 2026-08-05 | -$25.48M derived: sum of 3 quarters · filed 2026-08-05 | -$14.57M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$5.08M 10-Q · filed 2026-05-06 | -$33.61M derived: sum of 2 quarters · filed 2026-05-06 | -$22.70M derived: sum of 3 quarters · filed 2026-05-06 | -$29.09M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$28.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$17.63M derived: sum of 2 quarters · filed 2026-02-11 | -$24.01M derived: sum of 3 quarters · filed 2026-08-05 | -$13.93M 10-K · filed 2026-02-11 |
| 2025-09-30 | $10.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $4.52M derived: sum of 2 quarters · filed 2026-08-05 | $14.60M 10-Q · filed 2025-11-05 | $8.73M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$6.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $3.70M 10-Q · filed 2026-08-05 | -$2.17M derived: sum of 3 quarters · filed 2026-08-05 | $5.03M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $10.09M 10-Q · filed 2026-05-06 | $4.21M derived: sum of 2 quarters · filed 2026-05-06 | $11.42M derived: sum of 3 quarters · filed 2026-05-06 | $11.41M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$5.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.33M derived: sum of 2 quarters · filed 2026-02-11 | $1.32M derived: sum of 3 quarters · filed 2026-02-11 | -$2.29M 10-K · filed 2026-02-11 |
| 2024-09-30 | $7.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $7.20M derived: sum of 2 quarters · filed 2025-11-05 | $3.58M 10-Q · filed 2025-11-05 | $8.17M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | -$6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$3.62M 10-Q · filed 2025-08-06 | $966.00K derived: sum of 3 quarters · filed 2026-02-11 | $4.75M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | -$3.61M 10-Q · filed 2025-05-08 | $972.00K derived: sum of 2 quarters · filed 2026-02-11 | $4.76M derived: sum of 3 quarters · filed 2026-02-11 | $3.87M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $4.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $8.37M derived: sum of 2 quarters · filed 2026-02-11 | $7.49M derived: sum of 3 quarters · filed 2026-02-11 | $6.24M 10-K · filed 2026-02-11 |
| 2023-09-30 | $3.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $2.90M derived: sum of 2 quarters · filed 2024-11-06 | $1.65M 10-Q · filed 2024-11-06 | -$6.56M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | -$888.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$2.14M 10-Q · filed 2024-08-08 | -$10.34M derived: sum of 3 quarters · filed 2025-02-12 | -$6.41M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | -$1.25M 10-Q · filed 2024-05-09 | -$9.46M derived: sum of 2 quarters · filed 2025-02-12 | -$5.52M derived: sum of 3 quarters · filed 2025-02-12 | -$5.00K derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | -$8.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$4.27M derived: sum of 2 quarters · filed 2025-02-12 | $1.24M derived: sum of 3 quarters · filed 2025-02-12 | $2.29M 10-K · filed 2025-02-12 |
| 2022-09-30 | $3.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $9.45M derived: sum of 2 quarters · filed 2023-11-08 | $10.49M 10-Q · filed 2023-11-08 | $8.04M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $5.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $6.55M 10-Q · filed 2023-08-08 | $4.11M derived: sum of 3 quarters · filed 2024-02-15 | $2.88M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $1.04M 10-Q · filed 2023-05-09 | -$1.41M derived: sum of 2 quarters · filed 2024-02-15 | -$2.63M derived: sum of 3 quarters · filed 2024-02-15 | -$1.34M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | -$2.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$3.67M derived: sum of 2 quarters · filed 2024-02-15 | -$2.38M derived: sum of 3 quarters · filed 2024-02-15 | -$4.59M 10-K · filed 2024-02-15 |
| 2021-09-30 | -$1.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $69.00K derived: sum of 2 quarters · filed 2022-11-08 | -$2.14M 10-Q · filed 2022-11-08 | -$14.31M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | $1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$913.00K 10-Q · filed 2022-08-04 | -$13.08M derived: sum of 3 quarters · filed 2023-02-15 | -$15.54M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | -$2.21M 10-Q · filed 2022-05-05 | -$14.38M derived: sum of 2 quarters · filed 2023-02-15 | -$16.84M derived: sum of 3 quarters · filed 2023-02-15 | -$11.44M derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | -$12.17M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | -$14.63M derived: sum of 2 quarters · filed 2023-02-15 | -$9.23M derived: sum of 3 quarters · filed 2023-02-15 | -$766.00K 10-K · filed 2023-02-15 |
| 2020-09-30 | -$2.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $2.94M derived: sum of 2 quarters · filed 2021-11-10 | $11.40M 10-Q · filed 2021-11-10 | $16.52M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $5.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $13.86M 10-Q · filed 2021-08-11 | $18.98M derived: sum of 3 quarters · filed 2022-02-15 | $21.13M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $8.47M 10-Q · filed 2021-05-11 | $13.59M derived: sum of 2 quarters · filed 2022-02-15 | $15.73M derived: sum of 3 quarters · filed 2022-02-15 | |
| 2019-12-31 | $5.12M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $7.26M derived: sum of 2 quarters · filed 2022-02-15 | $6.50M 10-K · filed 2022-02-15 | |
| 2019-09-30 | $2.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $1.38M 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | -$769.00K 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | $1.35M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |